Pulse Biosciences, Inc.

As of October 31, 2025, Pulse Biosciences, Inc. shows a mildly bullish trend with supportive weekly indicators, despite some bearish signals on the weekly Dow Theory and recent underperformance against the S&P 500.

As of October 31, 2025, Pulse Biosciences, Inc. shows a mildly bullish technical trend, supported by positive moving averages and Bollinger Bands, despite mixed signals from MACD and Dow Theory, while underperforming the S&P 500 in the short term but outperforming over the last three years.

As of October 31, 2025, Pulse Biosciences, Inc. shows a mildly bullish trend supported by the weekly MACD and Bollinger Bands, despite mixed signals from the monthly MACD and Dow Theory, while underperforming the S&P 500 in the short term but significantly outperforming over the last three years.

As of September 26, 2025, Pulse Biosciences, Inc. shows a neutral technical trend with mixed indicators, mildly bullish weekly MACD and OBV, but mildly bearish monthly MACD and daily moving averages, while outperforming the S&P 500 in the short term but lagging year-to-date and over the past year.

As of September 26, 2025, Pulse Biosciences, Inc. shows a neutral trend with mixed technical indicators, mildly bullish on weekly MACD and OBV but mildly bearish on monthly MACD and daily moving averages, while it has outperformed the S&P 500 recently but lags behind year-to-date and yearly returns, suggesting a cautious approach.

As of September 12, 2025, Pulse Biosciences, Inc. is in a bearish trend with weak strength, despite recent short-term outperformance against the S&P 500, while showing mixed signals in technical indicators.

As of June 17, 2025, the technical trend is mildly bearish, influenced by bearish momentum from the weekly MACD and daily moving averages, despite mixed signals from Bollinger Bands and other indicators.

As of March 2022, the management team of Pulse Biosciences, Inc. includes Mr. Darrin Uecker as CEO and Independent Chairman Mr. Robert Duggan, along with several Independent Directors: Mr. Kenneth Clark, Mr. Mitchell Levinson, Mr. Manmeet Soni, and Dr. Mahkam Zanganeh.

Pulse Biosciences, Inc. is a clinical-stage medical device company specializing in non-thermal electroceutical treatment technology called Nano-Pulse stimulation. As of March 2025, it has a market cap of approximately $1.01 billion and reported a net profit loss of $17 million.

As of Jun 18, Pulse Biosciences, Inc. has a market capitalization of $1.01 billion, with net sales of $0.00 million and a net profit of -$60.25 million over the last four quarters. The company reported shareholder's funds of $114.86 million and total assets of $134.06 million as of Dec 24.